Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) Stock Competitors & Peer Comparison
See NNNN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NNNN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NNNN | $5.54 | -9.33% | 241.8M | 79.62 | $0.07 | N/A |
| ISRG | $385.13 | +1.90% | 133.2B | 39.21 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.13% |
| BDX | $184.20 | +0.71% | 51.2B | 14.30 | $13.00 | +2.13% |
| RMD | $227.67 | +2.10% | 33.3B | 21.32 | $10.77 | +1.06% |
| MDLN | $33.50 | +2.78% | 27.2B | 23.53 | $1.36 | N/A |
| WST | $361.98 | +1.91% | 25.7B | 42.93 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.53 | +0.79% | 15.6B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.13% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
NNNN vs ISRG Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, ISRG has a market cap of 133.2B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while ISRG trades at $385.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas ISRG's P/E ratio is 39.21. In terms of profitability, NNNN's ROE is +0.27%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, NNNN is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
NNNN vs BDXA Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas BDXA's P/E ratio is 45.70. In terms of profitability, NNNN's ROE is +0.27%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, NNNN is more volatile compared to BDXA. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
NNNN vs BDX Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, BDX has a market cap of 51.2B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while BDX trades at $184.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas BDX's P/E ratio is 14.30. In terms of profitability, NNNN's ROE is +0.27%, compared to BDX's ROE of +0.04%. Regarding short-term risk, NNNN is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
NNNN vs RMD Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, RMD has a market cap of 33.3B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while RMD trades at $227.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas RMD's P/E ratio is 21.32. In terms of profitability, NNNN's ROE is +0.27%, compared to RMD's ROE of +0.24%. Regarding short-term risk, NNNN is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
NNNN vs MDLN Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, MDLN has a market cap of 27.2B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while MDLN trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas MDLN's P/E ratio is 23.53. In terms of profitability, NNNN's ROE is +0.27%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, NNNN is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
NNNN vs WST Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while WST trades at $361.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas WST's P/E ratio is 42.93. In terms of profitability, NNNN's ROE is +0.27%, compared to WST's ROE of +0.19%. Regarding short-term risk, NNNN is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
NNNN vs HOLX Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas HOLX's P/E ratio is 31.54. In terms of profitability, NNNN's ROE is +0.27%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, NNNN is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
NNNN vs SOLV Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while SOLV trades at $90.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas SOLV's P/E ratio is 12.69. In terms of profitability, NNNN's ROE is +0.27%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, NNNN is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
NNNN vs BDXB Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas BDXB's P/E ratio is 7.60. In terms of profitability, NNNN's ROE is +0.27%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, NNNN is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
NNNN vs BAX Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while BAX trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas BAX's P/E ratio is 11.39. In terms of profitability, NNNN's ROE is +0.27%, compared to BAX's ROE of -0.17%. Regarding short-term risk, NNNN is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BAX's competition here
Avantor, Inc. (NYSE: AVTR)
NNNN vs AVTR Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while AVTR trades at $15.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas AVTR's P/E ratio is 18.15. In terms of profitability, NNNN's ROE is +0.27%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, NNNN is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check AVTR's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
NNNN vs COO Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, COO has a market cap of 10.4B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while COO trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas COO's P/E ratio is 11.68. In terms of profitability, NNNN's ROE is +0.27%, compared to COO's ROE of +0.07%. Regarding short-term risk, NNNN is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
NNNN vs RGEN Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, RGEN has a market cap of 9.9B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while RGEN trades at $174.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas RGEN's P/E ratio is 97.07. In terms of profitability, NNNN's ROE is +0.27%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, NNNN is more volatile compared to RGEN. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
NNNN vs ATR Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, ATR has a market cap of 8B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while ATR trades at $125.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas ATR's P/E ratio is 21.79. In terms of profitability, NNNN's ROE is +0.27%, compared to ATR's ROE of +0.14%. Regarding short-term risk, NNNN is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
NNNN vs BLCO Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while BLCO trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas BLCO's P/E ratio is 26.52. In terms of profitability, NNNN's ROE is +0.27%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, NNNN is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
NNNN vs STVN Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while STVN trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas STVN's P/E ratio is 32.57. In terms of profitability, NNNN's ROE is +0.27%, compared to STVN's ROE of +0.09%. Regarding short-term risk, NNNN is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
NNNN vs TFX Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while TFX trades at $129.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas TFX's P/E ratio is 14.75. In terms of profitability, NNNN's ROE is +0.27%, compared to TFX's ROE of -0.32%. Regarding short-term risk, NNNN is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
NNNN vs MMSI Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while MMSI trades at $86.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas MMSI's P/E ratio is 22.04. In terms of profitability, NNNN's ROE is +0.27%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, NNNN is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
NNNN vs NVST Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, NVST has a market cap of 4B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while NVST trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas NVST's P/E ratio is 16.85. In terms of profitability, NNNN's ROE is +0.27%, compared to NVST's ROE of +0.04%. Regarding short-term risk, NNNN is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
NNNN vs ICUI Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while ICUI trades at $158.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas ICUI's P/E ratio is 19.46. In terms of profitability, NNNN's ROE is +0.27%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, NNNN is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
NNNN vs PLSE Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while PLSE trades at $49.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas PLSE's P/E ratio is -46.78. In terms of profitability, NNNN's ROE is +0.27%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, NNNN is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
NNNN vs ATRC Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while ATRC trades at $56.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas ATRC's P/E ratio is 1745.96. In terms of profitability, NNNN's ROE is +0.27%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, NNNN is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
NNNN vs XRAY Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while XRAY trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas XRAY's P/E ratio is 6.87. In terms of profitability, NNNN's ROE is +0.27%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, NNNN is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
NNNN vs LMAT Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while LMAT trades at $80.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas LMAT's P/E ratio is 29.69. In terms of profitability, NNNN's ROE is +0.27%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, NNNN is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
NNNN vs BLFS Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while BLFS trades at $36.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas BLFS's P/E ratio is -172.18. In terms of profitability, NNNN's ROE is +0.27%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, NNNN is more volatile compared to BLFS. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
NNNN vs AZTA Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while AZTA trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas AZTA's P/E ratio is 78.64. In terms of profitability, NNNN's ROE is +0.27%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, NNNN is more volatile compared to AZTA. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
NNNN vs KMTS Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while KMTS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas KMTS's P/E ratio is -9.50. In terms of profitability, NNNN's ROE is +0.27%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, NNNN is more volatile compared to KMTS. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
NNNN vs STAA Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while STAA trades at $22.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas STAA's P/E ratio is 39.38. In terms of profitability, NNNN's ROE is +0.27%, compared to STAA's ROE of +0.01%. Regarding short-term risk, NNNN is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
NNNN vs ATRI Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas ATRI's P/E ratio is 64.50. In terms of profitability, NNNN's ROE is +0.27%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, NNNN is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
NNNN vs ANGO Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, ANGO has a market cap of 648.1M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while ANGO trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas ANGO's P/E ratio is -40.21. In terms of profitability, NNNN's ROE is +0.27%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, NNNN is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
NNNN vs SMTI Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, SMTI has a market cap of 322.8M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while SMTI trades at $35.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas SMTI's P/E ratio is -585.17. In terms of profitability, NNNN's ROE is +0.27%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, NNNN is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
NNNN vs EMBC Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, EMBC has a market cap of 302M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while EMBC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas EMBC's P/E ratio is 1.96. In terms of profitability, NNNN's ROE is +0.27%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, NNNN is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check EMBC's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
NNNN vs OSUR Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, OSUR has a market cap of 238.2M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while OSUR trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas OSUR's P/E ratio is -5.01. In terms of profitability, NNNN's ROE is +0.27%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, NNNN is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
NNNN vs UTMD Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, UTMD has a market cap of 237.6M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while UTMD trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas UTMD's P/E ratio is 22.08. In terms of profitability, NNNN's ROE is +0.27%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, NNNN is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
NNNN vs PDEX Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while PDEX trades at $72.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas PDEX's P/E ratio is 16.20. In terms of profitability, NNNN's ROE is +0.27%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, NNNN is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
NNNN vs KRMD Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while KRMD trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas KRMD's P/E ratio is -79.00. In terms of profitability, NNNN's ROE is +0.27%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, NNNN is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
NNNN vs STXS Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, STXS has a market cap of 129.3M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while STXS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas STXS's P/E ratio is -7.76. In terms of profitability, NNNN's ROE is +0.27%, compared to STXS's ROE of -1.33%. Regarding short-term risk, NNNN is more volatile compared to STXS. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
NNNN vs DXR Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, DXR has a market cap of 68M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while DXR trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas DXR's P/E ratio is 9.47. In terms of profitability, NNNN's ROE is +0.27%, compared to DXR's ROE of +0.13%. Regarding short-term risk, NNNN is more volatile compared to DXR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
NNNN vs AKYA Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas AKYA's P/E ratio is -1.34. In terms of profitability, NNNN's ROE is +0.27%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, NNNN is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
NNNN vs STSS Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas STSS's P/E ratio is -0.02. In terms of profitability, NNNN's ROE is +0.27%, compared to STSS's ROE of -1.54%. Regarding short-term risk, NNNN is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
NNNN vs OMIC Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas OMIC's P/E ratio is -0.58. In terms of profitability, NNNN's ROE is +0.27%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, NNNN is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
NNNN vs IGAP Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas IGAP's P/E ratio is -10.52. In terms of profitability, NNNN's ROE is +0.27%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, NNNN is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
NNNN vs NEPH Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, NEPH has a market cap of 46.6M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while NEPH trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas NEPH's P/E ratio is 71.50. In terms of profitability, NNNN's ROE is +0.27%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, NNNN is more volatile compared to NEPH. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
NNNN vs POCI Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, POCI has a market cap of 46.1M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while POCI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas POCI's P/E ratio is -6.68. In terms of profitability, NNNN's ROE is +0.27%, compared to POCI's ROE of -0.37%. Regarding short-term risk, NNNN is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
NNNN vs HBIO Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, HBIO has a market cap of 36M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while HBIO trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas HBIO's P/E ratio is -22.17. In terms of profitability, NNNN's ROE is +0.27%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, NNNN is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
NNNN vs MLSS Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, MLSS has a market cap of 35.5M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while MLSS trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas MLSS's P/E ratio is -8.02. In terms of profitability, NNNN's ROE is +0.27%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, NNNN is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
NNNN vs SDC Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas SDC's P/E ratio is -0.03. In terms of profitability, NNNN's ROE is +0.27%, compared to SDC's ROE of -1.96%. Regarding short-term risk, NNNN is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
NNNN vs IVC Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas IVC's P/E ratio is -0.79. In terms of profitability, NNNN's ROE is +0.27%, compared to IVC's ROE of -0.46%. Regarding short-term risk, NNNN is more volatile compared to IVC. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
NNNN vs RVP Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while RVP trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas RVP's P/E ratio is -5.67. In terms of profitability, NNNN's ROE is +0.27%, compared to RVP's ROE of -0.05%. Regarding short-term risk, NNNN is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
NNNN vs BNGO Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, BNGO has a market cap of 17.9M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while BNGO trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas BNGO's P/E ratio is -0.36. In terms of profitability, NNNN's ROE is +0.27%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, NNNN is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
NNNN vs ZJYL Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while ZJYL trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, NNNN's ROE is +0.27%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, NNNN is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
NNNN vs RGNT Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, RGNT has a market cap of 12.6M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas RGNT's P/E ratio is -0.07. In terms of profitability, NNNN's ROE is +0.27%, compared to RGNT's ROE of N/A. Regarding short-term risk, NNNN is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
NNNN vs CUPR Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, CUPR has a market cap of 7.9M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while CUPR trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas CUPR's P/E ratio is -2.12. In terms of profitability, NNNN's ROE is +0.27%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, NNNN is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
NNNN vs FEMY Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, FEMY has a market cap of 7.7M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while FEMY trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas FEMY's P/E ratio is -0.57. In terms of profitability, NNNN's ROE is +0.27%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, NNNN is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
NNNN vs LUCY Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while LUCY trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas LUCY's P/E ratio is -0.49. In terms of profitability, NNNN's ROE is +0.27%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, NNNN is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
NNNN vs NSTG Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas NSTG's P/E ratio is -0.03. In terms of profitability, NNNN's ROE is +0.27%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, NNNN is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
NNNN vs POAI Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas POAI's P/E ratio is -0.03. In terms of profitability, NNNN's ROE is +0.27%, compared to POAI's ROE of -21.19%. Regarding short-term risk, NNNN is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
NNNN vs MHUA Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas MHUA's P/E ratio is 0.25. In terms of profitability, NNNN's ROE is +0.27%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, NNNN is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
NNNN vs NXGL Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while NXGL trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas NXGL's P/E ratio is -0.40. In terms of profitability, NNNN's ROE is +0.27%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, NNNN is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
NNNN vs GMVD Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas GMVD's P/E ratio is -0.01. In terms of profitability, NNNN's ROE is +0.27%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, NNNN is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
NNNN vs GMVDW Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas GMVDW's P/E ratio is N/A. In terms of profitability, NNNN's ROE is +0.27%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, NNNN is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
NNNN vs AVGR Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas AVGR's P/E ratio is -0.05. In terms of profitability, NNNN's ROE is +0.27%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, NNNN is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
NNNN vs NXGLW Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, NNNN's ROE is +0.27%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, NNNN is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
NNNN vs LUCYW Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas LUCYW's P/E ratio is N/A. In terms of profitability, NNNN's ROE is +0.27%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, NNNN is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for NNNN.Check LUCYW's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
NNNN vs HRC Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, HRC has a market cap of 0. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas HRC's P/E ratio is 41.92. In terms of profitability, NNNN's ROE is +0.27%, compared to HRC's ROE of +0.14%. Regarding short-term risk, NNNN is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
NNNN vs ALOG Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, ALOG has a market cap of 0. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas ALOG's P/E ratio is 40.93. In terms of profitability, NNNN's ROE is +0.27%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, NNNN is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ALOG's competition here
Invuity, Inc. (NASDAQ: IVTY)
NNNN vs IVTY Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, IVTY has a market cap of 0. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas IVTY's P/E ratio is -3.80. In terms of profitability, NNNN's ROE is +0.27%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, NNNN is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check IVTY's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
NNNN vs ATRS Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, ATRS has a market cap of 0. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas ATRS's P/E ratio is 14.95. In terms of profitability, NNNN's ROE is +0.27%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, NNNN is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check ATRS's competition here
Apria, Inc. (NASDAQ: APR)
NNNN vs APR Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, APR has a market cap of 0. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas APR's P/E ratio is 22.59. In terms of profitability, NNNN's ROE is +0.27%, compared to APR's ROE of +9.81%. Regarding short-term risk, NNNN is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check APR's competition here
IntriCon Corporation (NASDAQ: IIN)
NNNN vs IIN Comparison September 2026
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NNNN stands at 241.8M. In comparison, IIN has a market cap of 0. Regarding current trading prices, NNNN is priced at $5.54 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NNNN currently has a P/E ratio of 79.62, whereas IIN's P/E ratio is 226.45. In terms of profitability, NNNN's ROE is +0.27%, compared to IIN's ROE of -0.00%. Regarding short-term risk, NNNN is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for NNNN.Check IIN's competition here